Monte Rosa Therapeutics (GLUE) Short-term Investments (2022 - 2023)
Monte Rosa Therapeutics (GLUE) recorded quarterly Short-term Investments of $960000.0 in Q1 2023, little changed quarter-over-quarter from $960000.0 in Q4 2022.
Monte Rosa Therapeutics (GLUE) Short-term Investments (2022 - 2023) Analysis & Trends
Monte Rosa Therapeutics' Short-term Investments history runs 2 years deep, the most recent figure standing at $960000.0 for Q1 2023.
- In Q1 2023, Short-term Investments changed N/A year-over-year to $960000.0; the TTM figure through Mar 2023 stood at $960000.0 (changed N/A YoY), while the FY2022 annual figure was $960000.0, changed N/A from the prior year.
- Short-term Investments was $960000.0 for Q1 2023 at Monte Rosa Therapeutics, roughly flat from $960000.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $960000.0 in Q3 2022 to a low of $960000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 960,000.00 |
| Dec 31, 2022 | 960,000.00 |
| Sep 30, 2022 | 960,000.00 |